EYLEA Significantly Reduced CRT at Year 1
Mean change in CRT through Years 1, 2, and 3 from baseline1-3,*
The results of these exploratory endpoints require cautious interpretation and could represent chance findings, as a multiplicity
adjustment has not been applied.
Anatomic measures were not used to influence treatment decisions.4
VISTA and VIVID Study Designs
Two randomized, multicenter, double-masked, controlled clinical studies in which patients with DME (N=862; age range: 23-87 years, with a mean of 63 years) were randomized and received: 1) EYLEA 2 mg Q8 following 5 initial monthly doses; 2) EYLEA 2 mg Q4; or 3) macular laser photocoagulation (control) at baseline and then as needed. Protocol-specified visits occurred every 28 (±7) days.4
In both clinical studies, the primary efficacy endpoint was the mean change from baseline in BCVA at Week 52, as measured by ETDRS letter score.4
Visual Acuity Gains in Patients With a Sustained DRSS Improvement
Mean change in BCVA (ETDRS letters) following EYLEA Q4 or Q8 in patients with a sustained Diabetic Retinopathy Severity Scale (DRSS)
improvement in Year 1 or 2 (post hoc analysis)3
The analyses of these post hoc endpoints were not multiplicity protected and are descriptive only.